Background
==========

Increasing numbers of breast cancer patients are treated with breast conserving surgery followed by systemic therapy and radiotherapy. Failure rates after breast conserving therapy (BCT) increase with 1--2% per year as reported by large centres \[[@B1]-[@B4]\] and even after mastectomy local recurrence rates might be as high as 40% depending on risk factors \[[@B5]\]. The treatment options for loco- regional recurrences are limited. Chemotherapy might not be effective in pre-irradiated tissue because a decreased perfusion can be expected due to radiation-induced fibrosis \[[@B6]\]. Mastectomy or local excision and reconstructive surgery are, thus, the preferred therapies. However, in recent years evidence accumulate that a second BCT might be feasible with long term local control. If cure is no longer achievable, local regional recurrences might cause suffering due to severe pain, bleeding and ulcerations in up to 62% of patients \[[@B7]\]. Furthermore, a growing tumour mass can be a stressful experience to a patient.

Retreatment with a second full course of radiation to the whole breast is used with caution as increased toxicity of skin and subcutaneous tissue is feared. Nevertheless, in recent years several investigators reported on reirradiation either alone or combined with concurrent hyperthermia or chemotherapy. Irradiation was applied as external beam therapy, brachytherapy or intraoperative radiotherapy.

The following report presents the experience of a single community centre with retreatment of loco-regional breast cancer recurrences after previous irradiation to the breast, chest wall, and/or regional lymphatic nodes. 3D conformal radiotherapy with or without concurrent 5-FU/capecitabine chemotherapy was given for operable and non-operable recurrences.

Methods
=======

Since 2003 we offer patients reirradiation of recurrent breast tumours based on recommendations of an interdisciplinary tumour board panel of gynaecology, medical oncology, diagnostic radiology and radiation oncology experts. This report is based on 29 patients treated with reirradiation. All data were prospectively collected. Written informed consent about the reirradiation procedure was given by all patients.

In 16 patients retreatment was offered because of bleeding, exulcerating and/or painful breast and/or local lymph node recurrences. Usually the patients had simultaneous distant metastases. No surgery of these recurrences was attempted except in one case with tumour debulking surgery. Usually, these patients had had multiple re-operations, chemotherapeutic or endocrine therapies and radiation treatment for distant metastases. Thirteen patients had no signs of distant metastases and surgery of the recurrences was done in all cases. The mean follow-up was 13.7 months (range 1.8 to 55.9 months) for all patients. Normal tissue toxicity was recorded according to the CTCAE (formerly known as CTC) v3.0 scoring system (Version 3.0; <http://ctep.cancer.gov>).

Patient characteristics
-----------------------

The median age was 62 years (range 35 to 82 yrs). The median interval between initial diagnosis and diagnosis before start of reirradiation was 70 months (range 10.3 to 295.5. Further details of tumour stage and recurrence site are given in table [1](#T1){ref-type="table"}.

###### 

Recurrent breast cancer treated with reirradiation.

  **Pat**.   **Age**   **TNM initial diagnosis**   **TNM reirradiation**   **Recurrence site**                  **Interval (months)**
  ---------- --------- --------------------------- ----------------------- ------------------------------------ -----------------------
  2          67        pT2pN0M0                    rT2R1G2M0               Infraclav., subpectoral right        137,4
  6          63        pT2pN1M0                    rpT2(m)R1NxL1M0G3       left thoracic wall                   25,2
  7          46        pT1R1pN0G3M0                rpT2RxM0                Caudal part of TRAM flap             225
  9          65        pT2pN1G3LOV0                rpT1rpN3G3M0 R1         Intramamm., IMC, v. subclavia        31,3
  15         66        pT2pN1M0                    rpT2R1G3 cN0 M0         Left thoracic wall                   164,8
  18         78        pT1bpN3G3R0M0               M1 (SKI) R1 G3          Lymphang. carc. left thoracic wall   10,3
  19         43        pT1bpN1G2L1R0               rpN2 R1 G2 M0           Left axilla, lateral thoracic wall   49,0
  23         58        pT1R1G2 pN0M0               rpT1c rpN R0 G2 M0      Mastectomy scar                      137,4
  24         50        pT3pN1G3                    rcN3 M1 (LYM)           LN level I-III, upper mediasti.LN    50,7
  25         62        pT1bpN0G2                   rpT1b G2 R0 pN0 M0      Lower left quadrant                  215,8
  26         71        pT3pN0M0 R1                 rpT2 G3 R0 M0           Medial part of left thoracic wall    295,5
  27         82        pT1pN1 G1M0                 rcT4 cN0 M0             Right lower inner quadrant           105,5
  28         44        pT1 G2 pN0 M0               rpT1b R0 G2 cN0 M0      Right upper outer quadrant           179,9
  1          67        pT1pN0Mo                    rcT4NxM0                Thoracic wall, extensive             181,7
  3          44        pT2pN1G3                    rcT4M1                  Thoracic wall, extensive             97,8
  4          49        pT1cpN0G3                   rpT2RxG3pNxM1           Thoracic wall + axilla               13,1
  5          35        pT3G3pN1M0                  rpT4G3N3M1              Left toracic wall, cutan. metast     21,1
  8          54        pT1pN0M0G3                  M1                      Parasternal recurrence               79,0
  10         63        pT4pN1M0                    rcN3M1                  Thoracic wall + axilla               56,0
  11         80        pT2pN0G2R0                  rpT4 R2 cN0M0           Lateral thoracic wall + axilla       70,7
  12         78        pT4bpN3M0G3R0,              rcN3M1                  Skin metast., LN supra., ax.         11,6
  13         71        pT1b GII pN1 M0             rcT4 N3 M0              Ax., supra. LN, mammary gland        50,6
  14         49        ypT1ypN1G3L1                rcN3M1                  Brachial plexus, skin metast.        39,2
  16         61        pT1pN1M0G2                  rcT4 M1                 Sternal and parasternal              190,3
  17         49        pT1pN2M0                    rcN3cM1                 Left supra., cervical LN             243,2
  20         46        pT3 pN1 M0 G3               rcT4 rcN3               Thoracic wall with ulceration        41,2
  21         70        pT2pN0M0R0                  rcT4Mx                  Thoracic wall, extensive             55,6
  22         44        cT4cNxM0                    rcT4Mx                  Thoracic wall, extensive             83,9
  29         79        pT1mpN2aM0                  rcT4 cN0 M0             Thoracic wall, extensive             36,8

Pat.: patient number; IMC: internal mammary chain; LN: lymph nodes.

Clinical characteristics of recurrent breast carcinoma patients treated with reirradiation. The initial and recurrence TNM staging and site of recurrence are shown. The interval between the initial diagnosis and diagnosis before start of retreatment is given in months.

Retreatment and statistical methods
-----------------------------------

Resection was incomplete or undefined (R1 or Rx) in 7/29. One patient had inoperable axillary and upper mediastinal lymph node metastases and one patient received preoperative reirradiation followed by mastectomy (R0). One patient had tumour debulking and axillary dissection before radiotherapy. All other patients were inoperable due to tumour extent and/or simultaneous distant disease.

All patients underwent computed tomography (n = 27) or FDG18-PET/CT (n = 2) for 3D-conformal radiotherapy planning. The dose per fraction was 1.6 to 2.5. The mean *total dose*(initial dose and reirradiation dose) of all patients was 106.2 Gy (range 80.4 to 126 Gy) and the mean total BED~3\ Gy~168,5 Gy (range 130,6 to 201,6).

The Biologically Effective Dose (BED) was calculated as follows:

where *n\*d*denotes the total dose and *d*the dose per fraction. α/β was assumed to be 3 Gy for late-responding tissues. The BED is the quantity by which different fractionation regimens can be compared. \[[@B8]\]

The mean interval between initial radiotherapy and reirradiation was 92.9 months (range 8.7 to 290.1). The *treatment volume*comprised all visible lesions or lesions detectable on on CT/MRI/FDG-PET/CT or the tumour bed or recurrent tumour. Treatment details with indication of the overlapping treatment volumes are shown in table [2](#T2){ref-type="table"}.

###### 

Recurrent breast cancer treated with reirradiation.

  **Pat**.   **Initial dose Gy**   **Reirrad. Dose (Gy)**   **Dose 1 +2 Gy**   **BED~3\ Gy~**   **Interval (m)**   **Overlapping treatment volume**   **Chemo-therapy**   **Surgery for recurrence**
  ---------- --------------------- ------------------------ ------------------ ---------------- ------------------ ---------------------------------- ------------------- --------------------------------
  2          55                    50,4                     105,4              178,1            133,6              Subpectoral + infraclavicular      5-FU                Segmental resection (BCT)
  6          60,4                  56                       116,4              182,5            20,4               Left thoracic wall                 none                mastectomy, ax. diss.
  7          60                    51,2                     101,2              188,5            220,5              Caudal thoracic wall               5-FU                Local excision
  9          45                    54,4                     99,4               155,4            26,8               Cranial thoracic wall              none                mastectomy, LN
  15         60                    51,2                     111,2              198,5            161,5              Mastectomy scar                    none                Thoracic wall resection,
  18         50                    57,6                     107,6              175,5            8,7                lateral thoracic wall, ax.         none                Local excision
  19         60,4                  61,2                     121,6              194,6            42,8               upper outer quadrant, ax.          Taxotere            resection, ax. diss. (BCT)
  23         60                    50,4                     110,4              180,6            135,1              Left thoracic wall                 none                reconstructive surgery
  24         60,4                  55,8                     116,2              185,9            42,5               Mastectomy scar                    Capecitab.          None
  25         60                    50,4                     110,4              180,6            212,6              Left lower quadrant                none                Local excision (BCT)
  26         50                    50,4                     100,4              172,3            290,1              Left thoracic wall                 none                Thoracic wall resection
  27         50                    46                       96                 160,0            114                Right lower inner quadrant         none                Mastectomy post- reirradiation
  28         60                    59,4                     119,4              195,0            175,0              Right upper quadrant               none                wide excision (BCT)
  1          50                    50,4                     100,4              164,0            184,7              Lateral thoracic wall              none                none
  3          50,4                  30                       80,4               130,6            32,5               Thoracic wall                      Capecitab.          None
  4          60                    45                       105                172,0            23,5               Thoracic wall                      Capecitab.          None
  5          64                    44,8                     108,8              175,4            52,6               Whole thoracic wall                Capecitab.          None
  8          60,4                  50                       110,4              180,0            85,9               parasternal                        none                None
  10         50,4                  57,6                     108                169,0            50,2               Thoracic wall                      5-FU                None
  11         66,6                  59,4                     126                201,6            69,5               Lat.thoracic wall                  none                None
  12         50,4                  45                       95,4               152,6            8,7                Thoracic wall, lateral             none                None
  13         60,0                  50,4                     110,4              180,6            49,9               Upper quadrants                    none                None
  14         60,4                  50,4                     110,8              177,3            28,7               Upper outer quadrant               5-FU                none
  16         55                    49                       104                186,6            185,2              parasternal                        none                None
  17         42,5                  45                       87,5               149,9            201,2              supraclav., apex ax.               none                None
  20         50                    48                       98                 163,3            32,7               Sternal + infraclav.               Capecitab.          None
  21         59,4                  44                       103,4              168,4            53,1               Thoracic wall                      none                None
  22         59,4                  46                       105,4              177,7            20,0               Thoracic wall                      none                None
  29         50,4                  50                       100,4              164,0            31,1               Thoracic wall                      none                None

Pat.: patient number ; BCT: breast conserving therapy for recurrence; LN: lymph nodes; ax. diss: axillary dissection; capecitab.: capecitabine.

Treatment details of recurrent breast carcinoma patients treated with reirradiation. Radiation doses (Gy) of initial radiotherapy and reirradiation, the cumulative dose (dose 1 + 2) and the cumulative BED~3\ Gy~(Gy) are shown. For the initial treatment, whole breast plus boost dose is given, if retreatment volume included the initial boost volume. The interval between the last day of the initial radiotherapy and first day of reirradiation is given in months.

Inoperable or incompletely resected patients were offered concurrent chemotherapy with either 5-FU (225 mg/sqm continuous infusion, seven days per week, during whole course of reirradiation) or capecitabine (1250 or 1650 mg bid during whole course of reirradiation) except in one case where docetaxel was given concurrently. All patients received chemotherapy *not*because of distant metastases but with the aim of an additional local effect. The minimum and maximum duration of chemotherapy was 3 weeks (with 30 Gy of reirradiation) and 5 weeks (reirradiation dose of ≥ 50 Gy). No chemotherapy was given to R0-resected patients. Due to multiple courses of chemotherapy because of metastatic disease and/or age and co-morbidities or refusal of patients not all could be treated with simultaneous chemotherapy. Endocrine therapy was given according to hormonal receptor status, i.e. premenopausal women received tamoxifen and postmenopausal women either an aromatase inhibitor or tamoxifen. Further details of retreatment for each patient are depicted in table [2](#T2){ref-type="table"}.

Patients were seen on follow-up visits 6 to 8 weeks after end of reirradiation and thereafter every 4 to 6 months. All other patients were contacted by telephone or their gynaecological and medical oncologist were interviewed.

Kaplan-Meier survival curves were generated with GraphPad Prism 5.0 (^©^1992--2007 Graph Pad Software Inc.).

Results
=======

In figure [1](#F1){ref-type="fig"} local progression-free survival is shown. The reported percentages indicate the local progression-free survival within the retreated volume (i.e. breast, chest wall, or supraclavicular/axillary lymph nodes). At one and two years the local progression-free survival was 81% and 63%. Those patients who had reirradiation because of non-operable recurrences (16/29) had local progression-free survival at one and two years of 72% and 25% with a median local progression-free survival time of 17 months (figure [2](#F2){ref-type="fig"}). Partial remission and good symptom relief was achieved in 56% (9/16) and complete response of symptoms and/or tumour in 44% (7/16). Nine of sixteen patients were free of local progressive disease during their lifetime. Overall survival times after one and two years were 61% and 40% and the median overall survival time was 20 months (inset of figure [2](#F2){ref-type="fig"}).

![**Local progression-free survival of reirradiated breast cancer patients (months after start of retreatment; n = 29).** A heterogeneous group of patients were retreated with operable (R1 or R0 resection) and non-operable recurrent breast tumours with and without distant metastases. Reirradiation was given alone or combined with simultaneous 5-fluoruracil or capecitabine to loco-regional breast cancer recurrences after previous irradiation to the breast, chest wall, and/or regional lymphatic nodes.](1748-717X-3-28-1){#F1}

![**Reirradiation of patients with non-operable recurrent breast carcinoma (n = 16).** Patients had either no surgery or only tumour debulking (n = 1). Local progression-free survival is shown (months after start or reirradiation). The inset depicts the overall survival percentage.](1748-717X-3-28-2){#F2}

The survival times of patients who had no distant metastases and who at least had a macroscopically complete resection (R1) of the recurrence are given in figure [3](#F3){ref-type="fig"}. The overall survival (figure [3A](#F3){ref-type="fig"}) was 92% and the local relapse free survival 90% (figure [3B](#F3){ref-type="fig"}) after 2 years. One patient (no. 8) had a local (infield) relapse in infra- and supraclavicular lymph nodes 19.7 months after reirradiation with 54,4 Gy (cumulative dose 99,4 Gy). She developed simultaneous lymph node metastases in the contralateral axilla. The relapse was documented on FDG-PET/CT and histological proven. As she was free of symptoms the patient decided to have no further treatment and is alive 11 months after the relapse (30,7 months after start of reirradiation). A second patient (no. 19) developed a simultaneous inflammatory recurrence of the whole breast and bone metastases 15.8 months after start of reirradiation. She is alive and receives chemotherapy.

![**Reirradiation of recurrent breast carcinoma. Survival proportions of a subgroup of patients (n = 13) are shown who were free of distant metastases at the time of diagnosis of the recurrence and who were operable (R0 or R1-resection).** Kaplan-Meier curves for overall survival (panel A), local relapse-free survival (panel B), and disease-free survival (panel C) are given.](1748-717X-3-28-3){#F3}

The disease-free survival after 2 years was 42% and the median disease-free survival time was 24 months (figure [3C](#F3){ref-type="fig"}). One patient had intracerebral metastases which were treated with stereotactic radiotherapy. She died 28,5 months after reirradiation with no signs of a local recurrence within the reirradiated breast. One patient (no. 2) had multiple bone and cerebral metastases 8,5 months after reirradiation. She is alive with disease 26,5 months after reirradiation. One patient suffered from a contra lateral breast cancer 20.6 months after reirradiation and skin metastases. She was treated with trastuzumab and a taxane and is alive 31,8 months after reirradiation. One male patient with a recurrent breast cancer (no. 18) had skin metastases outside the retreatment volume at the medial parts of the thoracic wall and upper abdominal wall 6,9 months after reirradiation. He received taxanes and had a complete response. He is alive 15,2 months after reirradiation.

In three patients a second breast conserving operation was performed and the cosmetic results in all three patients are excellent (1) or good (2).

Normal tissue toxicity
----------------------

Acute side effects were mild to moderate (skin erythema grade 1 to 2) in *all*patients with no grade 3 or 4 toxicity. Accordingly, no grade 3 or 4 late effects were observed so far. One patient developed a rib fracture 330 days after reirradiation within an overlapping region receiving a total dose of 95 Gy (1.8 Gy/fraction). Pain was mild to moderate and pain medication was only temporarily necessary. No cases with grade 3 or 4 plexopathy were observed so far.

Discussion
==========

We treated a heterogeneous group of 29 patients suffering from recurrent breast cancer after previous radiotherapy. Reirradiation was given with cumulative total doses of 80.4 to 126 Gy applied with or without concurrent chemotherapy. Palliation was good to excellent in all patients lasting for a long time of the patients\' lifetime in the majority of cases. Bearing in mind the short median follow up, two infield recurrences were detected. Acute and late tolerances are good to excellent with no grade 3 or 4 normal tissue toxicity.

Techniques of reirradiation vary and may be applied with brachytherapy, intraoperative radiotherapy or external beam radiation. In general, literature on reirradiation in breast cancer is rare and not available on a systematic basis concerning radiation techniques.

Repeat high-dose partial breast irradiation after excision of an in-breast recurrence was offered 39 women who have refused mastectomy or were considered suitable for repeat lumpectomy with reirradiation by Deutsch \[[@B9]\]. The local recurrence-free survival was 76.9% after reirradiation with a median follow-up of 51.5 months, the overall survival 77.9% at 5 years. The distant metastases rate was 20.5%. The cosmetic results were excellent or good in 27 patients. In nine patients the cosmetic outcome was fair or poor.

Harms et al. \[[@B10]\] treated 58 patients with local recurrences (31 had concomitant distant metastases) after mastectomy and postoperative radiotherapy (mean dose 52 Gy). Retreatment consisted of pulsed-dose-rate brachytherapy (PDR brachytherapy) with two fractions of 22 and 18 Gy or twice 20 Gy separated by an interval of 30 days were applied. The two and 3 year locoregional recurrence-free survival rates for R2-resected tumours were 81% and 75%, for R1- resected tumours 85% and 71%, respectively. The majority of macroscopic tumour recurrences (R2) had a complete remission (28/30) after reirradiation. The normal tissue toxicity seemed to be rather high with grade 3/4 toxicity of 22% comprising in the majority of cases marked teleangiectasia and less often skin contracture. Pulsed-dose-rate brachytherapy was also used by Resch and colleagues \[[@B11]\] who re-treated 17 patients with small local recurrences with local excision and either a combination of PDR brachytherapy (total dose 12.5 -- 28 Gy) and EBRT (total dose 12--30 Gy) or PDR brachytherapy alone. The initial radiation dose to the whole breast plus tumour bed was 50 to 60 Gy. The cumulative radiation was approximately 100 Gy as stated by the authors without details for individual patients. Four patients (24%) had second recurrences all within one year after retreatment and underwent mastectomy. No patient with PDR brachytherapy alone and retreatment doses of 40.2 to 50 Gy experienced a local recurrence. Biologically a dose of 40 to 50 Gy given within 4 days can be expected to be more efficient than a conventional fractionated EBRT given within five weeks. Skin and subcutaneous tissue side effects were moderate with no grade 3 or 4 toxicity. No unacceptable, i.e. deformities of the breast, results were observed and 5/17 had good to excellent results.

A case report of a 63-year-old female patient with left ductal breast cancer 13 years after primary treatment (mastectomy, axillary dissection, and 50 Gy postoperative irradiation) was published by Mayer at al. \[[@B12]\]. Perioperative HDR-AL with Ir-192 was performed with a dose per fraction of 6 Gy to the reference line, two fractions per week, to a total dose of 30 Gy. The tumour was locally controlled and the patient disease-free at five years. Skin toxicity did not exceed grade 2.

A novel technique to irradiate patients is intraoperative radiotherapy with a 50 kV X-rays source (Intrabeam™) treating patients during surgery and limiting radiation dose to the tumour bed. Kraus-Tiefenbacher et al. \[[@B13]\] reported on 17 patients with in-breast recurrences reirradiated with the Intrabeam™ source (median dose 20 Gy to the applicator surface). Note that the dose distribution by the Intrabeam™ source is characterized by a sharp dose fall off, i.e. in 1 cm depth from the applicator surface only 5 Gy are delivered. As the dose per fraction is high and the radiobiology is different from fractionated Megavoltage treatment with external beam irradiation, a direct comparison of both modalities is difficult. After a median follow-up of 26 months 16/17 patients were still alive, one patient died 26 months IORT due to pulmonary metastases (19 months after retreatment). Two other patients had distant metastases but were alive. No local recurrences were observed. Acute toxicity was mild with no Grade 3/4 toxicities and there was no delay in wound healing or wound infection. The cosmetic outcome was rated in the majority of cases as good to excellent, at least as fair.

The largest number of reirradiated patients were reported by Kapp et al. \[[@B14]\] and van der Zee et al. \[[@B15],[@B16]\] in combination with hyperthermia. Kapp et al. reported on 89 patients of which about half had prior radiation therapy (the exact number was not given) with an average dose auf 50,6 Gy. These patients received reirradiation with a total dose of 35 to 40 Gy (dose/fraction 1.8 to 2.1 Gy) to the ecisional biopsy in conjunction with hyperthermia. The average cumulative total dose was probably 90 Gy though no details were reported on individual patients. Longer duration of local control was achieved with concurrent reirradiation doses greater 39,5 Gy. The local failure rate was 24% in the subset of patients with biopsies only.

J. van der Zee and colleagues first published in 1988 on ninety-seven patients with recurrent breast cancer previously irradiated \[[@B15]\]. Reirradiation without prior surgery was given twice weekly with 2 to 4 Gy per fraction to a total dose of 8 to 32 Gy. The high dose per fraction was probably given because of the palliative intention and the fact that most patients were heavily pre-treated with different kinds of chemotherapy and endocrine therapy. The cumulative dose was 40 to 96 Gy. Hyperthermia was applied concurrently. The time interval between first and second radiation therapy was 1 to 203 months, mean 48 months. A complete response was achieved in 35% and a partial response in 55%. In many patients no local progression occurred during their lifetime. The authors concluded that 8 × 4 Gy in conjunction with hyperthermia is safe and feasible without severe toxicity. In 1999 the authors published a second study \[[@B16]\] with longer follow up and more patients. The minimum time interval between first and second radiation course was 4 months. Again, a single dose of 4 Gy was given twice weekly concurrent with hyperthermia, total dose 12 to 32 Gy (129/134). A clinical complete response rate of macroscopic tumours of 71% was achieved. Within the group of completely responding tumours or reirradiation after R1-resection, approx. 30% recurred in-field after a median follow up of 11 months. The median duration of local control was 32 months. Moderate to marked erythema was observed in 48/134 patients, ulcerations in 14 patients (nine had tumour-induced ulcerations before start of retreatment).

Phromratanapongse and colleagues reported in 1993 on 44 patients with locally recurrent, previously irradiated adenocarcinoma of the breast \[[@B17]\]. Hyperthermia was combined with concurrent radiation doses varying from 16 to 56 Gy. In 41% of these inoperable recurrences a complete response could be achieved with low acute toxicity. Two had ulcerations with infection and one patient severe blisters.

Inoperable recurrent breast cancer in fifteen patients, who had undergone a radical mastectomy and conventional radiotherapy (60 Gy), were entered on a multimodal protocol consisting of initial treatment with radiotherapy and a monthly infusion of liposomal doxorubicin in conjunction with local hyperthermia treatment \[[@B18]\]. All patients received reirradiation up to a total dose of 30.6 Gy in 1.8 Gy/fraction. All patients showed an objective measurable response and 3 patients (20%) demonstrated a clinically complete response.

In the current study, part of the patients also received concurrent chemotherapy with either continuous infusion 5-FU or capecitabine (one case with docetaxel) in inoperable or incompletely resected patients. The rationale for choosing concurrent chemotherapy was the expectation of an additional locoregional. In head and neck cancer reirradiation combined with chemotherapy results in prolonged survival and long term survival in some patients \[[@B19]\]. As the current study was not a randomized one examining reirradiation alone with combined chemotherapy and reirradiation, we cannot quantify the additional effect of chemotherapy. We chose 5-FU or capecitabine because of extensive clinical experience in combined modality treatment and the low risk of excessive skin toxicity with these substances. Cisplatin or docetaxel, however, might well be good alternatives as these agents are widely used in the combination with radiotherapy e.g. in head and neck cancer.

Conclusion
==========

Including the results of this study, data on more than 300 patients reirradiated for recurrent breast cancer either alone or in combination with chemo-endocrine treatment and/or hyperthermia have so far been published. Reirradiation is feasible and save at least within the first five years after retreatment with low to modest side effects offering a second curative chance *with*breast conserving therapy. In palliative intended treatment, results are good to excellent lasting for most of the patients\' lifetime. The minimum time interval between first and second radiation treatment should be six months based on published data although the exact time interval is unknown. The duration and percentage of local control is dose dependent. The minimum second radiation dose in fractionated irradiation should be 40 Gy though higher doses might be possible depending on the treatment volume. With regard to possible late side effects, we recommend a dose per fraction of 1.8 to 2 Gy in curative intent. Higher doses per fraction can be given in patients expecting a lifetime of only a few months. Reirradiation can be safely combined with continuous infusion 5-FU or oral capecitabine. Possible alternative radiation techniques to fractionated Megavoltage external beam therapy are brachytherapy and intraoperative radiation therapy.
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